Patient Support

Marketed as cost-saving tools, AFPs can also strain safety-net resources.

Experts from Moderna, Revelation Pharma, and Alexion offer ways to reduce risks, improve real-time visibility, and ensure product integrity in the growing ship-to-home market.

Supply chain leaders share strategies to address persistent drug shortages, highlighting vulnerabilities, manufacturing complexities, and the importance of cross-industry collaboration.

Capturing insights from executives and industry experts on the biggest challenges shaping pharma today, from drug pricing pressures and access barriers to supply chain shifts, digital adoption, and evolving patient-centered care strategies.

Through its “BMS Patient Connect” platform, the company is lowering out-of-pocket costs and providing nationwide shipping, making the treatment for affordable and accessible for US patients.

The platform enables clinicians to tailor GLP-1 titration at scale, aiming to reduce discontinuation rates and improve long-term outcomes for patients undergoing obesity treatment.

Takeda will be shipping treatments between Europe and the US using VELA’s sailing cargo trimaran, potentially reducing greenhouse gas emissions by up to 99% when compared with air freight.

A new JAMA Network Open study highlights how over-the-counter oral contraceptives can reduce barriers to care, especially for uninsured, rural, and adolescent populations, amid shifting federal policies on reproductive health.

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.

By reducing waste, improving forecasting, and strengthening payer negotiations, these technologies are helping pharmaceutical companies unlock efficiency, accelerate adoption, and differentiate in competitive markets.

In the first part of their Pharma Commerce video interview, Boyede Sobitan and Annika Matas of Zebra Technologies warn that ongoing medication shortages are forcing staff to borrow supplies, delay procedures, and divert nurses from patient care to logistical tasks, creating both financial pressures and operational inefficiencies.

In the final part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, focuses on physician demand, global momentum, and how US legislation can help the industry finally move beyond paper.

In the second part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, highlights that cutting down on the 90 billion sheets of paper used for medicine inserts each year isn’t just an environmental win—it’s also a critical step toward making drug information more accessible for patients with vision challenges, language barriers, or cognitive and physical disabilities.

This episode of Pharma Pulse covers the FDA’s approval of Sanofi’s Wayrilz for chronic immune thrombocytopenia, evidence that prescription-to-OTC switches of triptans improve migraine care access, and new FDA guidance waiving clinical efficacy studies for most monoclonal antibody biosimilars.

In the first part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, explains how the Prescription Information Modernization Act of 2025 aims to replace package inserts with digital-first documentation, providing patients with better access to understandable medication guidance in the process.

In the final part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, emphasizes that patient access must remain the top priority, even amid steep tariffs, citing cases like orphan drugs and oncology treatments where government flexibility is essential.

As of today, Aug. 27, wholesale distributors must fully comply with the Drug Supply Chain Security Act’s enhanced drug distribution requirements, closing the FDA’s exemption period and advancing efforts to strengthen patient safety and supply chain integrity.

The merger integrates EVERSANA’s commercialization services with Waltz Health’s AI-powered payer tools to address patient affordability, streamline drug access, and reduce costs for high-expense therapies such as GLP-1s.

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a promising drug combination against resistant influenza strains, and how community pharmacies are strengthening healthcare access in underserved areas.

This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to support safe use, adherence, and management of related chronic health needs.

This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results showing mail-order and supermarket pharmacies outpacing traditional chains in customer satisfaction, and rising affordability pressures as insurers restrict GLP-1 coverage.

In the first part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, warns that counterfeiters are using generative AI to clone pharmaceutical packaging, build convincing fake websites, and manipulate search results. rapidly outpacing enforcement efforts and putting patients at serious risk.

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate discounts, and limited transparency.

In the first part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, explains how steep pharmaceutical import tariffs might affect costs at different points in the supply chain, why component pricing poses a bigger risk than active ingredients, and how insurers, distributors, and manufacturers may negotiate to shield patients from price increases.